(RTTNews) - Horizon Therapeutics plc (HZNP) announced that its phase 2, randomized, double-blinded, placebo-controlled trial of dazodalibep in rheumatoid arthritis met the primary endpoint. Dazodalibep was also well tolerated in the trial.
In the phase 2 trial, approximately 75 subjects with active, moderate-to-severe, adult-onset rheumatoid arthritis were randomized into four different dosing regimens or a placebo arm. The study met its primary endpoint of change from baseline in DAS28-CRP at day 113 in all four dazodalibep dosing arms, the company said.
"It is promising to see that the dazodalibep phase 2 rheumatoid arthritis trial not only met the primary endpoint, but that the observed treatment effect was consistently maintained," said Theresa Podrebarac, senior vice president, clinical development, Horizon.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
